TITLE

FDA APPROVES BIOVAIL'S GENERIC PROCARDIA XL 30MG DOSAGE

PUB. DATE
March 2001
SOURCE
Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the final approval granted by the United States Food and Drug Administration to Biovail Corporation's generic Procardia XL drug.
ACCESSION #
4155584

 

Related Articles

  • FTC overturns generic pact.  // Medical Marketing & Media;Aug2002, Vol. 37 Issue 8, p20 

    Reports that the U.S. Federal Trade Commission has forced Bioavail Corp. and Elan Corp. to terminate their non-compete agreements for sales of the generic versions of the antihypertensive Adalat CC. Details of the proposed consent order.

  • FTC Sides with Generics Industry. Kelley, Gordon // Pharmaceutical Executive;Jun2002 Supplement, Vol. 23, p23 

    Reports on the action taken by the U.S. Federal Trade Commission (FTC) against pharmaceutical companies who delay generic introductions. Attempt of Biovail to use ancillary patent filings to delay generic competition of its heart drug Tiazac; Investigation of FTC of the delaying tactics of...

  • BIOVAIL EXTENDS MARKETING PACT FOR ZOVIRAX OINTMENT/CREAM.  // Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p2 

    Reports on the extension of the marketing agreement between Biovail Corp. and GlaxoSmithKline Plc for the Zovirax (R) Ointment and Zovirax Cream, as of February 2003.

  • A tough pill to swallow. Sparks, Debra // Financial World;11/18/96, Vol. 165 Issue 14, p42 

    Questions the valuation of the stock of Biovail, which has launched the hypertension drug Tiazac. Institutional investors buying into the company; Competition posed by Cardizem, another drug; Consequences of the failure to genericize Procardia XL.

  • Canadian pharmaceutical to expand. Garza, Daniel R. // Caribbean Business;3/4/1999, Vol. 27 Issue 8, p2 

    Focuses on the additional employees projected by Biovail Corp. for its pharmaceutical manufacturing facility in Puerto Rico following the approval of its hypertension drug by the United States Food & Drug Administration (FDA).

  • Forest to bid.  // Crain's New York Business;9/18/95, Vol. 11 Issue 38, p50 

    Reports on Forest Laboratories Inc.'s plan to announce a tender offer of 22% of Biovail Corp. International as part of a licensing agreement for Biovail's approved heart drug.

  • Biova Retains Ford Levine Sales Group.  // Nutraceuticals World;May2013, Vol. 16 Issue 4, p22 

    The article reports that the Ford Levine Sales Group for natural markets and international sales development has been retained by Biova Corp. in the U.S.

  • Biovale to provide 150 more jobs. Ruano, Lida Estela // Caribbean Business;12/28/1995, Vol. 23 Issue 52, p4 

    Reports that Biovale Corporation based in Canada, plans to develop a 150-job plant in Puerto Rico, which will produce products for sale in the United States market in the year 1997. Comments from Economic Development Administrator Jaime Morgan Stubbe.

  • Generics. Scheller, Melanie // Current Health 2;Dec96, Vol. 23 Issue 4, p30 

    Provides information on generic drugs. Differentiation of generic drugs from brand name drugs; Pricing difference between generics and brand name drugs; Drug effectiveness.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics